Aimovig vs Emgality
Side-by-side cost comparison based on Medicare Part D data
Aimovig
Erenumab
Manufactured by Amgen/Novartis
Emgality
Galcanezumab
Manufactured by Eli Lilly
Emgality costs 3% less per claim than Aimovig ($688.00 vs $706.00). A generic version of Emgality is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Aimovig | Emgality |
|---|---|---|
| Avg Cost Per Claim | $706.00 | $688.00 |
| Total Medicare Spending | $876.0M | $678.0M |
| Total Beneficiaries | 148,000 | 112,000 |
| Total Claims | 1,240,000 | 986,000 |
| Annual Cost/Patient | $5,919.00 | $6,054.00 |
| Year-over-Year Change | +8.4% | +14.8% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Amgen/Novartis | Eli Lilly |
| Condition | Migraine | Migraine |
| Generic Name | Erenumab | Galcanezumab |
Aimovig vs Emgality: What the Data Shows
Aimovig (Erenumab) and Emgality (Galcanezumab) are both used to treat migraine. Based on Medicare Part D data, Emgality costs $688.00 per claim, which is 3% less than Aimovig at $706.00 per claim.
Medicare spent $876.0M on Aimovig and $678.0M on Emgality. In terms of patient reach, Aimovig serves more beneficiaries (148,000 vs 112,000).
Year-over-year spending changed +8.4% for Aimovig and +14.8% for Emgality. Emgality saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Emgality is cheaper at $688.00 per claim, compared to $706.00 for Aimovig. That makes Emgality about 3% less expensive per claim based on Medicare Part D data.
Yes, both Aimovig and Emgality are used to treat migraine. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Erenumab and generic Galcanezumab can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $876.0M on Aimovig covering 148,000 beneficiaries, and $678.0M on Emgality covering 112,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.